|
1
|
Welzel TM, McGlynn KA, Hsing AW, O’Brien
TR and Pfeiffer RM: Impact of classification of hilar
cholangiocarcinomas (Klatskin tumors) on the incidence of intra-
and extrahepatic cholangiocarcinoma in the United States. J Natl
Cancer Inst. 98:873–875. 2006. View Article : Google Scholar
|
|
2
|
Luke C, Price T and Roder D: Epidemiology
of cancer of the liver and intrahepatic bile ducts in an Australian
population. Asian Pac J Cancer Prev. 11:1479–1485. 2010.PubMed/NCBI
|
|
3
|
Khan SA, Taylor-Robinson SD, Toledano MB,
Beck A, Elliott P and Thomas HC: Changing international trends in
mortality rates for liver, biliary and pancreatic tumours. J
Hepatol. 37:806–813. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Patel T: Worldwide trends in mortality
from biliary tract malignancies. BMC Cancer. 2:102002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Patel T: Cholangiocarcinoma -
controversies and challenges. Nat Rev Gastroenterol Hepatol.
8:189–200. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Arrington AK, Nelson RA, Falor A, Luu C,
et al: Impact of medical and surgical intervention on survival in
patients with cholangiocarcinoma. World J Gastrointest Surg.
5:178–186. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
DeOliveira ML, Cunningham SC, Cameron JL,
et al: Cholangiocarcinoma: thirty-one-year experience with 564
patients at a single institution. Ann Surg. 245:755–762.
2007.PubMed/NCBI
|
|
8
|
Hemming AW, Reed AI, Fujita S, Foley DP
and Howard RJ: Surgical management of hilar cholangiocarcinoma. Ann
Surg. 241:699–702. 2005. View Article : Google Scholar
|
|
9
|
Ramirez-Merino N, Aix SP and Cortes-Funes
H: Chemotherapy for cholangiocarcinoma: An update. World J
Gastrointest Oncol. 5:171–176. 2013. View Article : Google Scholar
|
|
10
|
Zografos GN, Farfaras A, Zagouri F,
Chrysikos D and Karaliotas K: Cholangiocarcinoma: principles and
current trends. Hepatobiliary Pancreat Dis Int. 10:10–20. 2011.
View Article : Google Scholar
|
|
11
|
Alberts SR, Al-Khatib H, Mahoney MR, et
al: Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary
tract and gallbladder carcinoma: a North Central Cancer Treatment
Group phase II trial. Cancer. 103:111–118. 2005. View Article : Google Scholar
|
|
12
|
Patt YZ, Hassan MM, Aguayo A, et al: Oral
capecitabine for the treatment of hepatocellular carcinoma,
cholangiocarcinoma, and gallbladder carcinoma. Cancer. 101:578–586.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Woo SM, Lee WJ, Han SS, et al:
Capecitabine plus cisplatin as first-line chemotherapy for advanced
biliary tract cancer: a retrospective single-center study.
Chemotherapy. 58:225–232. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maithel SK, Gamblin TC, Kamel I,
Corona-Villalobos CP, Thomas M and Pawlik TM: Multidisciplinary
approaches to intrahepatic cholangiocarcinoma. Cancer.
22:3929–3942. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Barney BM, Olivier KR, Miller RC and
Haddock MG: Clinical outcomes and toxicity using stereotactic body
radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol.
7:672012. View Article : Google Scholar
|
|
16
|
Gonzalez Gonzalez D, Gouma DJ, Rauws EA,
van Gulik TM, Bosma A and Koedooder C: Role of radiotherapy, in
particular intraluminal brachytherapy, in the treatment of proximal
bile duct carcinoma. Ann Oncol. 10(Suppl 4): 215–220.
1999.PubMed/NCBI
|
|
17
|
Isayama H, Tsujino T, Nakai Y, et al:
Clinical benefit of radiation therapy and metallic stenting for
unresectable hilar cholangiocarcinoma. World J Gastroenterol.
18:2364–2370. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McMasters KM, Tuttle TM, Leach SD, Rich T,
Cleary KR, Evans DB and Curley SA: Neoadjuvant chemoradiation for
extrahepatic cholangiocarcinoma. Am J Surg. 174:605–608. 1997.
View Article : Google Scholar
|
|
19
|
Brunner TB and Eccles CL: Radiotherapy and
chemotherapy as therapeutic strategies in extrahepatic biliary duct
carcinoma. Strahlenther Onkol. 186:672–680. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ghafoori AP, Nelson JW, Willett CG, et al:
Radiotherapy in the treatment of patients with unresectable
extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys.
81:654–659. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mladenov E, Magin S, Soni A and Iliakis G:
DNA double-strand break repair as determinant of cellular
radiosensitivity to killing and target in radiation therapy. Front
Oncol. 3:1132013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Baumann M, Krause M and Hill R: Exploring
the role of cancer stem cells in radioresistance. Nat Rev Cancer.
8:545–554. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Balcer-Kubiczek EK: Apoptosis in radiation
therapy: a double-edged sword. Exp Oncol. 34:277–285.
2012.PubMed/NCBI
|
|
24
|
Shimura T: Acquired radioresistance of
cancer and the AKT/GSK3beta/cyclin D1 overexpression cycle. J
Radiat Res. 52:539–544. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K
and Linn S: Molecular mechanisms of mammalian DNA repair and the
DNA damage checkpoints. Annu Rev Biochem. 73:39–85. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schmitt CA: Senescence, apoptosis and
therapy - cutting the lifelines of cancer. Nat Rev Cancer.
3:286–295. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kawabe T: G2 checkpoint abrogators as
anticancer drugs. Mol Cancer Ther. 3:513–519. 2004.PubMed/NCBI
|
|
28
|
Bucher N and Britten CD: G2 checkpoint
abrogation and checkpoint kinase-1 targeting in the treatment of
cancer. Br J Cancer. 98:523–528. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lapenna S and Giordano A: Cell cycle
kinases as therapeutic targets for cancer. Nat Rev Drug Discov.
8:547–566. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ma Z, Yao G, Zhou B, Fan Y, Gao S and Feng
X: The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer
cells to radiation in vitro and in vivo. Mol Med Rep.
6:897–903. 2012.PubMed/NCBI
|
|
31
|
Riesterer O, Matsumoto F and Wang L: A
novel Chk inhibitor, XL-844, increases human cancer cell
radiosensitivity through promotion of mitotic catastrophe. Invest
New Drugs. 29:514–522. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tandle AT, Kramp T, Kil WJ, et al:
Inhibition of polo-like kinase 1 in glioblastoma multiforme induces
mitotic catastrophe and enhances radiosensitisation. Eur J Cancer.
49:3020–3028. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tang Y, Dai Y, Grant S and Dent P:
Enhancing CHK1 inhibitor lethality in glioblastoma. Cancer Biol
Ther. 13:379–388. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Maruyama M, Kobayashi N, Westerman KA, et
al: Establishment of a highly differentiated immortalized human
cholangiocyte cell line with SV40T and hTERT. Transplantation.
77:446–451. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hematulin A, Sagan D, Eckardt-Schupp F and
Moertl S: NBS1 is required for IGF-1 induced cellular proliferation
through the Ras/Raf/MEK/ERK cascade. Cell Signal. 20:2276–2285.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Morgan MA, Parsels LA, Zhao L, et al:
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762
involves abrogation of the G2 checkpoint and inhibition of
homologous recombinational DNA repair. Cancer Res. 70:4972–4981.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tepsiri N, Chaturat L, Sripa B, Namwat W,
Wongkham S, Bhudhisawasdi V and Tassaneeyakul W: Drug sensitivity
and drug resistance profiles of human intrahepatic
cholangiocarcinoma cell lines. World J Gastroenterol. 11:2748–2753.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Deodato F, Clemente G, Mattiucci GC, et
al: Chemoradiation and brachytherapy in biliary tract carcinoma:
long-term results. Int J Radiat Oncol Biol Phys. 64:483–488. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bonkhoff H: Factors implicated in
radiation therapy failure and radiosensitization of prostate
cancer. Prostate Cancer. 2012:5932412012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Coventry BJ and Ashdown ML: Complete
clinical responses to cancer therapy caused by multiple divergent
approaches: a repeating theme lost in translation. Cancer Manag
Res. 4:137–149. 2012. View Article : Google Scholar
|
|
41
|
Fei P and El-Deiry WS: P53 and radiation
responses. Oncogene. 22:5774–5783. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mazzatti DJ, Lee YJ, Helt CE, O’Reilly MA
and Keng PC: p53 modulates radiation sensitivity independent of p21
transcriptional activation. Am J Clin Oncol. 28:43–50. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lu C and El-Deiry WS: Targeting p53 for
enhanced radio- and chemo-sensitivity. Apoptosis. 14:597–606. 2009.
View Article : Google Scholar : PubMed/NCBI
|
